Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2011 2
2012 2
2013 1
2014 1
2016 3
2017 1
2018 5
2019 4
2020 11
2021 12
2022 16
2023 9
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL, McCoy KS; VX17-445-103 Trial Group. Heijerman HGM, et al. Among authors: van braeckel e. Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31. Lancet. 2019. PMID: 31679946 Free PMC article. Clinical Trial.
Aspergillus and the Lung.
Janssens I, Lambrecht BN, Van Braeckel E. Janssens I, et al. Among authors: van braeckel e. Semin Respir Crit Care Med. 2024 Feb;45(1):3-20. doi: 10.1055/s-0043-1777259. Epub 2024 Jan 29. Semin Respir Crit Care Med. 2024. PMID: 38286136 Free PMC article. Review.
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
Sutharsan S, McKone EF, Downey DG, Duckers J, MacGregor G, Tullis E, Van Braeckel E, Wainwright CE, Watson D, Ahluwalia N, Bruinsma BG, Harris C, Lam AP, Lou Y, Moskowitz SM, Tian S, Yuan J, Waltz D, Mall MA; VX18-445-109 study group. Sutharsan S, et al. Among authors: van braeckel e. Lancet Respir Med. 2022 Mar;10(3):267-277. doi: 10.1016/S2213-2600(21)00454-9. Epub 2021 Dec 20. Lancet Respir Med. 2022. PMID: 34942085 Clinical Trial.
A complement atlas identifies interleukin-6-dependent alternative pathway dysregulation as a key druggable feature of COVID-19.
Van Damme KFA, Hoste L, Declercq J, De Leeuw E, Maes B, Martens L, Colman R, Browaeys R, Bosteels C, Verwaerde S, Vermeulen N, Lameire S, Debeuf N, Deckers J, Stordeur P, Depuydt P, Van Braeckel E, Vandekerckhove L, Guilliams M, Schetters STT, Haerynck F, Tavernier SJ, Lambrecht BN. Van Damme KFA, et al. Among authors: van braeckel e. Sci Transl Med. 2023 Aug 23;15(710):eadi0252. doi: 10.1126/scitranslmed.adi0252. Epub 2023 Aug 23. Sci Transl Med. 2023. PMID: 37611083
The pathophysiology of 'happy' hypoxemia in COVID-19.
Dhont S, Derom E, Van Braeckel E, Depuydt P, Lambrecht BN. Dhont S, et al. Among authors: van braeckel e. Respir Res. 2020 Jul 28;21(1):198. doi: 10.1186/s12931-020-01462-5. Respir Res. 2020. PMID: 32723327 Free PMC article. Review.
Gastro-intestinal manifestations in cystic fibrosis patients.
Van Biervliet S, de Clercq C, Declercq D, Van Braeckel E, Van Daele S, De Baets F, De Looze D. Van Biervliet S, et al. Among authors: van braeckel e. Acta Gastroenterol Belg. 2016 Sep-Dec;79(4):481-486. Acta Gastroenterol Belg. 2016. PMID: 28209107 Free article. Review.
The Spectrum of Pulmonary Aspergillosis.
Van Braeckel E, Cornely OA. Van Braeckel E, et al. Semin Respir Crit Care Med. 2024 Feb;45(1):1-2. doi: 10.1055/s-0043-1778126. Epub 2024 Jan 29. Semin Respir Crit Care Med. 2024. PMID: 38286135 No abstract available.
Bronchiectasis and asthma: Data from the European Bronchiectasis Registry (EMBARC).
Polverino E, Dimakou K, Traversi L, Bossios A, Haworth CS, Loebinger MR, De Soyza A, Vendrell M, Burgel PR, Mertsch P, McDonnell M, Škrgat S, Maiz Carro L, Sibila O, van der Eerden M, Kauppi P, Hill AT, Wilson R, Milenkovic B, Menendez R, Murris M, Digalaki T, Crichton ML, Borecki S, Obradovic D, Nowinski A, Amorim A, Torres A, Lorent N, Welte T, Blasi F, Van Braeckel E, Altenburg J, Shoemark A, Shteinberg M, Boersma W, Elborn JS, Aliberti S, Ringshausen FC, Chalmers JD, Goeminne PC; EMBARC registry investigators. Polverino E, et al. Among authors: van braeckel e. J Allergy Clin Immunol. 2024 Jun;153(6):1553-1562. doi: 10.1016/j.jaci.2024.01.027. Epub 2024 Feb 23. J Allergy Clin Immunol. 2024. PMID: 38401857 Free article.
The nutritional status in CF: Being certain about the uncertainties.
Declercq D, Van Meerhaeghe S, Marchand S, Van Braeckel E, van Daele S, De Baets F, Van Biervliet S. Declercq D, et al. Among authors: van braeckel e. Clin Nutr ESPEN. 2019 Feb;29:15-21. doi: 10.1016/j.clnesp.2018.10.009. Epub 2018 Nov 7. Clin Nutr ESPEN. 2019. PMID: 30661680 Review.
65 results